An announcement from Candel Therapeutics ( (CADL) ) is now available.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Candel Therapeutics has reported promising results from its ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade glioma, showing improved survival rates for some patients. The trial data, presented at the International Oncolytic Virotherapy Conference, suggests CAN-3110 triggers immune system activation and tumor clearance. With its innovative viral immunotherapy approach, Candel is making strides in developing effective cancer treatments and expanding its clinical pipeline.
See more insights into CADL stock on TipRanks’ Stock Analysis page.